Synopsis : Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announced today that Dr. Dominic F.…
Diagnostics
-
-
RegulatoryU.S FDA
Positive Phase III Data Lifts Madrigal, Hopes for an Effective NASH Treatment
by adminby adminSynopsis : Shares of Madrigal Pharmaceuticals went up in premarket trading after the company announced positive topline data from its Phase III…
-
AgrochemicalsGlobal Market
Biogen Departure Train Chugs on as Two Board Members Exit
by adminby adminSummary : One week after Johnna Rossell departed Biogen for Enzyvant, the embattled company announced that two members of its board of…
-
AgrochemicalsGlobal Market
Biogen Recoups Much-Needed $2.3B with Sale of Samsung Bioepis Stake
by adminby adminSynopsis : Biogen is selling its nearly 50% stake in South Korea-based Samsung Bioepis for $2.3 billion. The move will provide Biogen…
-
AgrochemicalsGlobal Market
Lithium-Sparing Alzheimer’s Therapy has Strong Benefit-to-Risk Profile
by adminby adminCourtesy of Alzamend Neuro On the strength of data from its Phase 1 Study of lead compound, AL001, being developed for…
-
AgrochemicalsGlobal Market
Gene genies: Oxford Biomedica and Homology Medicines create AAV business
by adminby adminSummary : Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new U.S.-based AAV Manufacturing and Innovation Business Homology…
-
AgrochemicalsGlobal Market
Enrol call: Verona recruits 800 patients for COPD trial
by adminby adminSummary : The phase 3 trial involved over 800 candidates to assess ensifentrine when administered as a maintenance therapy to patients diagnosed…
-
AgrochemicalsGlobal MarketPharma Science & Research
NIH awards $170 million for Precision Nutrition Study
by adminby adminSynopsis : The National Institutes of Health (NIH) is awarding $170 million over five years, pending the availability of funds, to clinics…
-
AgrochemicalsGlobal Market
Oncolytics Biotech provides enrollment update on multi-indication phase 1/2 gastrointestinal cancer trial at 2022 ASCO-GI symposium
by adminby adminSummary : Successfully enrolled first-line metastatic pancreatic and third-line metastatic colorectal safety run-ins Company moving to full enrollment pending independent safety review…
-
Summary – Lupin Diagnostics, a 100 percent subsidiary of Lupin Limited, has set up a state-of-the-art 45,000 sq. ft National Reference Laboratory…